Clinical Trials Browser

INDUSTRY × Interventional × Metastatic Castration-resistant Prostate Cancer × Clear all

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Clinical Trials

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

AlphaBreak

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

ProTACT

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

SYNERGY-201

PRESERVE-006

Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets

A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

LUCIDA

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Phase 0/1 Study of 212Pb-NG001 in mCRPC

Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)

Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer

Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC